Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker TEVA · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Nov 9, 2026 | ANASTROZOLE ANASTROZOLE | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement Labeling | ANDA078058 ↗ |
| Nov 3, 2026 | FLUTICASONE PROPIONATE FLUTICASONE PROPIONATE | TEVA Teva Pharmaceuticals USA Inc | Generic (ANDA) UNKNOWN | ANDA209917 ↗ |
| Oct 27, 2026 | RIVAROXABAN RIVAROXABAN | TEVA Teva Pharmaceuticals USA | Generic (ANDA) UNKNOWN | ANDA212247 ↗ |
| Oct 19, 2026 | DEFLAZACORT DEFLAZACORT | TEVA Teva Pharmaceuticals Inc | Generic (ANDA) UNKNOWN | ANDA217103 ↗ |
| Oct 15, 2026 | MESALAMINE MESALAMINE | TEVA Teva Pharmaceuticals Inc | Generic (ANDA), supplement Labeling | ANDA213191 ↗ |
| Oct 15, 2026 | MESALAMINE MESALAMINE | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement Labeling | ANDA207873 ↗ |
| Oct 8, 2026 | WELTRUZA OLANZAPINE | TEVA Teva | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA219007 ↗ |
| Oct 7, 2026 | CLARAVIS ISOTRETINOIN | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement REMS | ANDA076356 ↗ |
| Oct 7, 2026 | CLARAVIS ISOTRETINOIN | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement REMS | ANDA076135 ↗ |
| Oct 6, 2026 | PROGLYCEM DIAZOXIDE | TEVA Teva Branded Pharm | New drug (NDA), supplement Labeling | NDA017453 ↗ |
| Sep 29, 2026 | PONLIMSI DENOSUMAB-ADET | TEVA Teva Pharmaceuticals, Inc. | Biologic (BLA), supplement BIOSIMILAR | BLA761385 ↗ |
| Sep 28, 2026 | DEXMETHYLPHENIDATE HYDROCHLORIDE DEXMETHYLPHENIDATE HYDROCHLORIDE | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement Labeling | ANDA077107 ↗ |
| Sep 28, 2026 | DEXMETHYLPHENIDATE HYDROCHLORIDE DEXMETHYLPHENIDATE HYDROCHLORIDE | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement Labeling | ANDA077107 ↗ |
| Sep 28, 2026 | DEXMETHYLPHENIDATE HYDROCHLORIDE DEXMETHYLPHENIDATE HYDROCHLORIDE | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement Labeling | ANDA077107 ↗ |
| Sep 25, 2026 | DEGEVMA DENOSUMAB-ADET | TEVA Teva Pharmaceuticals, Inc. | Biologic (BLA) Type 5 - New Formulation or New Manufac… | BLA761481 ↗ |
| Sep 24, 2026 | DORZOLAMIDE HYDROCHLORIDE DORZOLAMIDE HYDROCHLORIDE | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement Labeling | ANDA078756 ↗ |
| Sep 17, 2026 | PALONOSETRON HYDROCHLORIDE PALONOSETRON HYDROCHLORIDE | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement Labeling | ANDA090713 ↗ |
| Sep 15, 2026 | CARBAMAZEPINE CARBAMAZEPINE | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement Labeling | ANDA078592 ↗ |
| Sep 11, 2026 | PACLITAXEL PACLITAXEL | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement Labeling | ANDA075184 ↗ |
| Aug 21, 2026 | CLARAVIS ISOTRETINOIN | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement Labeling | ANDA076356 ↗ |
| Aug 21, 2026 | CLARAVIS ISOTRETINOIN | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement Labeling | ANDA076135 ↗ |
| Aug 17, 2026 | TOFACITINIB CITRATE TOFACITINIB CITRATE | TEVA Teva Pharmaceuticals USA | Generic (ANDA) UNKNOWN | ANDA209813 ↗ |
| Aug 14, 2026 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement REMS | ANDA091149 ↗ |
| Aug 11, 2026 | VARDENAFIL HYDROCHLORIDE VARDENAFIL HYDROCHLORIDE | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement Labeling | ANDA091347 ↗ |
| Aug 11, 2026 | GLIPIZIDE AND METFORMIN HYDROCHLORIDE GLIPIZIDE; METFORMIN HYDROCHLORIDE | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement Labeling | ANDA077270 ↗ |
| Aug 11, 2026 | METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE | TEVA Teva | Generic (ANDA), supplement Labeling | ANDA076864 ↗ |
| Aug 11, 2026 | GLYBURIDE AND METFORMIN HYDROCHLORIDE GLYBURIDE; METFORMIN HYDROCHLORIDE | TEVA Teva | Generic (ANDA), supplement Labeling | ANDA076821 ↗ |
| Aug 11, 2026 | METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE | TEVA Teva | Generic (ANDA), supplement Labeling | ANDA076269 ↗ |
| Jul 29, 2026 | MYCOPHENOLATE MOFETIL MYCOPHENOLATE MOFETIL | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement REMS | ANDA211272 ↗ |
| Jul 29, 2026 | MYCOPHENOLATE SODIUM MYCOPHENOLATE SODIUM | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement REMS | ANDA202720 ↗ |
| Jul 29, 2026 | MYCOPHENOLATE MOFETIL MYCOPHENOLATE MOFETIL | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement REMS | ANDA065491 ↗ |
| Jul 29, 2026 | MYCOPHENOLATE MOFETIL MYCOPHENOLATE MOFETIL | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement REMS | ANDA065457 ↗ |
| Jul 28, 2026 | SUGAMMADEX SODIUM SUGAMMADEX SODIUM | TEVA Teva Pharmaceuticals USA Inc | Generic (ANDA) UNKNOWN | ANDA214126 ↗ |
| Jul 24, 2026 | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE | TEVA Teva Branded Pharm | New drug (NDA), supplement Labeling | NDA020186 ↗ |
| Jul 21, 2026 | TOLVAPTAN TOLVAPTAN | TEVA Teva Pharmaceuticals Inc | Generic (ANDA) UNKNOWN | ANDA216933 ↗ |
| Jul 13, 2026 | ELTROMBOPAG OLAMINE ELTROMBOPAG OLAMINE | TEVA Teva Pharmaceuticals USA | Generic (ANDA) UNKNOWN | ANDA209938 ↗ |
| Jul 2, 2026 | FINASTERIDE FINASTERIDE | TEVA Teva | Generic (ANDA), supplement Labeling | ANDA076511 ↗ |
| Jun 26, 2026 | ARGATROBAN IN 0.9% SODIUM CHLORIDE ARGATROBAN | TEVA Teva Pharmaceuticals USA | New drug (NDA), supplement Labeling | NDA206769 ↗ |
| Jun 26, 2026 | NILOTINIB HYDROCHLORIDE NILOTINIB HYDROCHLORIDE | TEVA Teva Pharmaceuticals Inc | Generic (ANDA) UNKNOWN | ANDA219134 ↗ |
| Jun 22, 2026 | COPAXONE GLATIRAMER ACETATE | TEVA Teva Pharmaceuticals USA | New drug (NDA), supplement Labeling | NDA020622 ↗ |
| Jun 22, 2026 | LO JUNEL FE ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | TEVA Teva Pharmaceuticals Inc | Generic (ANDA) UNKNOWN | ANDA219324 ↗ |
| Jun 18, 2026 | MORPHINE SULFATE MORPHINE SULFATE | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement REMS | ANDA202718 ↗ |
| Jun 18, 2026 | OXYMORPHONE HYDROCHLORIDE OXYMORPHONE HYDROCHLORIDE | TEVA Teva | Generic (ANDA), supplement REMS | ANDA091443 ↗ |
| Jun 18, 2026 | TRAMADOL HYDROCHLORIDE TRAMADOL HYDROCHLORIDE | TEVA Teva | Generic (ANDA), supplement REMS | ANDA075977 ↗ |
| Jun 8, 2026 | MACITENTAN MACITENTAN | TEVA Teva Pharmaceuticals USA Inc | Generic (ANDA) UNKNOWN | ANDA211187 ↗ |
| Jun 8, 2026 | RISEDRONATE SODIUM RISEDRONATE SODIUM | TEVA Teva Pharmaceuticals USA | Generic (ANDA), supplement Labeling | ANDA077132 ↗ |
| Jun 5, 2026 | AJOVY FREMANEZUMAB-VFRM | TEVA Teva Pharmaceuticals USA | Biologic (BLA), supplement Labeling | BLA761089 ↗ |
| May 27, 2026 | LINAGLIPTIN LINAGLIPTIN | TEVA Teva Pharmaceuticals USA | Generic (ANDA) UNKNOWN | ANDA208433 ↗ Letter or label ↗ |
| May 7, 2026 | LOSARTAN POTASSIUM LOSARTAN POTASSIUM | TEVA Teva | Generic (ANDA), supplement Labeling | ANDA076958 ↗ |
| May 7, 2026 | GABAPENTIN GABAPENTIN | TEVA Teva Pharmaceuticals | Generic (ANDA), supplement Labeling | ANDA075435 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 7:32 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates